The U.S. has a new most reputable pharma company: Horizon Therapeutics. In a survey (PDF) of U.S. patient groups, Horizon was the only company to keep its position in the top three, with Roche and Servier rising to displace ViiV Healthcare and Pfizer from the other two spots on the leaderboard.
As it has done for more than a decade, PatientView created the ranking by collecting the views of patient groups in the U.S., on this occasion by surveying 361 organizations from late 2022 to early 2023.
Horizon had the best overall corporate reputation among the respondents, rising one place from 2021 in what could be its final year as an independent company. Amgen is set to buy Horizon for $28.3 billion.
Limiting the analysis to patient groups that work with the companies changed the leaderboard slightly, with Vertex taking the No. 2 spot and pushing Servier out of the top three. The finding reflects a shift in the perception of Vertex, which was one of the biggest risers, both among patient groups that are familiar with it and those that work directly with the Big Biotech. Bayer was another big riser.
Horizon held the No. 1 spot on both lists, though. According to Horizon, the patient groups that work with it put it in the top spot across 11 of the 14 indicators tracked by PatientView. The company topped the rankings for the indicators acting with integrity, employing a strong patient-centric approach, providing high-quality information for patients and ensuring that more...
Park Filed Complaint Against President Lee Ahead of 2021 Election Jang Youngha Sentenced to One Year in Prison, Two Years Probation Confirmed The police have launched an investigation into Park Chu...